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The field of radiochemistry is moving toward exclusive use of automated synthesis modules for production of clinical
radiopharmaceutical doses. Such a move comes with many advantages, but also presents radiochemists with the challenge
of re-configuring synthesis modules for production of radiopharmaceuticals that require nonconventional radiochemistry
while maintaining full automation. This review showcases the versatility of the Tracerlab FXFN synthesis module by
presenting simple, fully automated methods for producing [18F]FLT, [18F]FAZA, [18F]MPPF, [18F]FEOBV, [18F]sodium fluoride,
[18F]fluorocholine and [18F]SFB.
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Introduction
The field of radiochemistry is increasingly migrating toward the use
of commercially available automated synthesis modules for
production of clinical radiopharmaceutical doses. The advantages
of such a strategy over more traditional ‘manual’ synthetic
approaches are clear and include: (i) automation of radiochemical
syntheses providing robust, repeatable processes; (ii) the ability to
handle multiple Curies of radioactivity safely enabling positron
emission tomography (PET) Centers to produce and distribute
hundreds of doses daily; (iii) facilitated regulatory compliance
through manufacturer IQ/OQ/PQ and scheduled maintenance
protocols performed on synthesis modules by authorized person-
nel; and (iv) improved radiation safety through elimination of
manual operations. Despite these numerous significant advan-
tages, the move toward exclusive use of automated synthesis
modules also has some associated challenges. Chief among these
is the issue of re-configuring synthesis modules for production of
radiopharmaceuticals that require nonconventional radiochemistry
(such radiochemical strategies have been the subject of several
recent major review articles1–10) while maintaining full automation.
Furthermore, what is the best method to simplify making such
frequently nontrivial changes in module configuration so that
multiple operators can make them with a minimal chance for error?
At the University of Michigan PET Center, fluorine-18-labeled
radiopharmaceuticals (with the exception of [18F]FDG) are
prepared using General Electric Medical Systems (GEMS) Tracer-
Lab FXFN automated synthesis modules. As the demand for
clinical doses of different fluorine-18-labeled radiopharmaceuti-
cals, many of which are prepared using complex radiochemical
techniques, continues to increase, we11–13 and others14–22 have
had to address the issue of frequent synthesis module
reconfiguration. For example, recently we reported reconfigura-
tion of a TracerLab FXC-Pro to allow preparation of multiple
carbon-11-labeled radiopharmaceuticals without the need to
open the hot-cell door between syntheses,12 and modifications to
a TracerLab FXFN enabling production of [
18F]sodium fluoride to
address the ongoing technetium-99m isotope shortage.13
In this overview we report configurational changes to a
TracerLab FXFN that allow for straightforward switching between
production of [18F]-labeled radiopharmaceuticals using routine
methods and those prepared using less common radiochemical
techniques (e.g. gas phase reactions). Proof-of-concept is
demonstrated through the simple, fully automated, production
of multiple different [18F]-labeled radiopharmaceuticals using a
single TracerLab FXFN (Figure 1).
Automated radiopharmaceutical production
using a tracerlab FXFN
Introduction
General modifications to the tracerlab FXFN
The Tracerlab FXFN synthesis module is installed ‘out-of-the-box’
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configuration is suitable for straightforward production of
radiopharmaceuticals requiring HPLC purification (e.g. FLT or
FAZA, discussed in Tracerlab Production with HPLC Purification
section) and can easily be reconfigured to incorporate a
reformulation (e.g. for production of MPPF or FEOBV, discussed
in Tracerlab Production with HPLC Purification and SPE Reformu-
lation section and illustrated in Figure 7). However, with some
simple modifications the TracerLab FXFN can also be used to
produce radiopharmaceuticals using other strategies such as the
gas phase reactions outlined elsewhere in this article.
The first modification involves the delivery line from the
cyclotron target. This line was originally just pushed through a
hole in the septum of the target vial. However, if this line is clipped
in half and the two parts re-connected using luer lock fittings,
then target delivery can easily be switched between the target vial
and, for example, the round-bottomed dilution flask (necessary for
production of [18F]sodium fluoride as discussed in Tracerlab
Production with SPE Purification section) or directly on to a QMA
Sep-Pak, with minimal risk of damaging the delivery line. The latter
approach of trapping a target dump directly onto a QMA Sep-Pak
has been adapted by our group for straightforward and safe
transportation of fluoride to satellite PET centers. The QMA Sep-
Pak is housed in a lead pig prior to fluoride-18 delivery (Figure 2),
and the luer lock fitting on the cyclotron delivery line is connected
to the lines of the QMA delivery system. After fluoride delivery, the
delivery line can easily be disconnected and the pig safely
transferred to a DOT approved Type A container for transport.
The second modification to the Tracerlab FXFN is similar, and
involves incorporating luer lock fittings into both the line
connecting V-18 to the round-bottomed dilution flask and also
the line connecting V-17 to the round-bottomed dilution flask.
These fittings are essential for production of [18F]sodium
fluoride, [18F]fluorocholine and [18F]SFB, as discussed in Tracer-
lab Production with SPE Purification section. Reflecting the fact
that these modifications are only to tubing and fittings, defined 29
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Figure 1. Fluorine-18-labeled radiopharmaceuticals.
Figure 2. Setup for fluoride-18 distribution.
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as consumables and customer responsible maintenance items
by GEMS, they do not invalidate the manufacturer IQ/OQ.
In order to verify that the alternative synthesis module
configurations are suitable, three process verification (qualifica-
tion) runs are completed for each radiopharmaceutical prior to
preparation of clinical doses.
General synthesis considerations
Unless otherwise stated, reagents and solvents were commer-
cially available and used without further purification:
sodium chloride, 0.9% USP and Sterile Water for Injection, USP
were purchased from Hospira; ethanol was purchased from
American Regent; anhydrous acetonitrile, potassium carbonate,
sodium acetate, hydrochloric acid, sodium dihydrogenpho-
sphate, dribromomethane, acetic acid, DMSO, DIPEA, tetrapro-
pylammonium hydroxide and TSTU were purchased from
Sigma Aldrich; kryptofix-2.2.2 was purchased from Acros
Organics and HPLC grade acetonitrile was purchased from
Fisher Scientific.
Precursors and standards were commercially available unless
otherwise indicated. FLT (standard and DMT-Boc-Nosyl/cyclic
precursors), MPPF (standard and precursor), fluorocholine
(standard) and SFB (standard and precursor) were purchased
from ABX Advanced Biochemicals. Sodium fluoride and
dimethylamino ethanol (fluorocholine precursor) were pur-
chased from Sigma Aldrich. Boc-Boc-Nosyl FLT precursor is the
intellectual property of Siemens Molecular Imaging and
Biomarker Research. [18F]FAZA precursor and unlabeled refer-
ence standard were purchased from Prof. Friedrich Hammersch-
midt (Universität Wien, Austria) and Prof. Hans-Jürgen Machulla
(Steinbeis Transfer Center Radiopharmacy, Germany), and used
as received. [18F]FEOBV standard and precursor were synthe-
sized in house.
Other synthesis components were obtained as follows: sterile
filters were obtained from Millipore; sterile product vials were
purchased from Hollister-Stier; [18O]H2O was purchased from
ABX Advanced Biochemical Compounds; silica, plus-CM light,
alumina-light, C18-light and QMA-light Sep-Paks were pur-
chased from Waters Corporation. Plus-CM light, alumina-light,
C18-light and QMA-light Sep-Pak’s were flushed with 10 mL of
ethanol followed by 10 mL of sterile water prior to use. Silica
Sep-Paks were used for preparation of [18F]fluorocholine with-
out preconditioning.
General procedure for azeotropic drying of [18F]fluoride
Fluoride-18 at the University of Michigan was produced via the
18O(p,n)18F nuclear reaction using a GEMS PETTrace cyclotron
equipped with a high yield fluorine-18 target. Fluoride-18 was
delivered from the cyclotron (in a 1.5 mL bolus of [18O]H2O) and
trapped on a QMA-light Sep-Pak to remove [18O]H2O. Fluoride-
18 was then typically eluted into the reaction vessel using
aqueous potassium carbonate (3.0–3.5 mg in 0.4–0.5 mL water).
A solution of kryptofix-2.2.2 (15–20 mg in 1 mL of acetonitrile)
was then added to the reaction vessel and the fluoride-18 was
dried by evaporating the water–acetonitrile azeotrope. Evapora-
tion of the azeotrope was achieved by heating the reaction
vessel to 801C and drawing full vacuum for 4 min. After this time,
the reaction vessel was cooled to 601C and subjected to both an
argon stream and the vacuum simultaneously for an additional
4 min.
Tracerlab production with HPLC purification
Production of [18F]FLT
Introduction: 30-Deoxy-30-[18F]-fluorothymidine ([18F]FLT) is a PET
tracer based upon the DNA base thymidine. FLT does not get
incorporated into DNA directly, but is similar enough to
thymidine that it gets phosphorylated by the same enzyme
(thymidine kinase-1) and trapped in the cell. Therefore, it can be
used to image tumor cell proliferation. FLT was originally reported
by Shields et al. in 199823 and, after extensive development over
the last decade, is now in global clinical trials. For example, FLT is
in Phase 2/3 clinical trials in the United States and the Society of
Nuclear Medicine (SNM) has a multi-center Investigational New
Drug (IND) application approved by the US Food and Drug
Administration (FDA). These factors all indicate that FLT is en route
to becoming a standard of care PET biomarker for oncologists
and to date it has been used to effectively diagnose and monitor
many different cancers, including brain, lung, breast and
esophageal tumors. A Scifinder search for [18F]FLT returns over
200 articles and referencing all of them is beyond the scope of
this paper. However, the extensive use of [18F]FLT in oncological
PET imaging has been recently reviewed by Been et al.24
A number of synthetic routes and precursors have been
reported for the production of [18F]FLT with varying degrees of
success.17,25–29 The [18F]FLT production method disclosed herein
has been tested using the Boc-Boc-Nosyl, DMT-Boc-Nosyl and
2,30-anhydro-cyclic precursors and all can be used to prepare
[18F]FLT. We have found the Boc-Boc-Nosyl precursor, reported by
Walsh and Padgett,25 very effective because it provides [18F]FLT in
high yields (23% nondecay corrected) and eliminates purification
and QC issues associated with DMT contaminants, although to
the best of our knowledge this precursor is not yet commercially
available. Therefore, in addition to the Boc-Boc-Nosyl method, a
synthetic strategy using the standard commercially available 2,30-
anhydro-cyclic precursor is also reported herein.
Synthesis procedures
Method A: Boc-Boc-Nosyl precursor: To prepare FLT using
Method A, the Tracerlab synthesis module was used in the
original ‘out-of-the-box’ configuration illustrated in Figure 3 and
reagent vials were loaded as follows: Vial 1: potassium carbonate
(3.0 mg in 0.4 mL water); Vial 2: kryptofix-2.2.2 (20 mg in 1 mL
MeCN); Vial 3: Boc-Boc-Nosyl FLT precursor (17.5 mg in 1.0 mL
MeCN); Vial 4: HCl (1M, 1.0 mL); Vial 5: Aq. NaOAc (2 M, 0.5 mL).
Following drying of the fluoride using the general procedure,
Boc-Boc-Nosyl FLT precursor (17.5 mg in 1 mL MeCN) was added
and the reaction vessel was heated at 1351C for 3 min. The
acetonitrile reaction solvent was then evaporated and 1 M HCl
(1.0 mL) was added to remove the Boc groups. The deprotection
was heated at 1101C for 5 min after which time the reaction vessel
was cooled to room temperature and neutralized with 2 M NaOAc
(0.5 mL). The crude reaction mixture was diluted, passed through
an alumina Sep-Pak to remove unreacted fluoride-18 and purified
by semi-preparative HPLC (column: Phenomonex Synergi Hydro-
RP, 250 10 mm; mobile phase: 8% EtOH : 92% 21 mM sodium
phosphate (v/v); flow rate: 5.5 mL/min). A typical trace is shown in
Figure 4. The peak corresponding to [18F]FLT was collected into
the collection vial of the TracerLab, from which it was then passed
through an alumina Sep-Pak and sterile filter into a sterile dose
vial. Doses were released for quality control testing as described
in Quality Control Procedures section, and the yield of [18F]FLT
using this method is 23% (nondecay corrected, n = 5).29
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Figure 4. Semi-preparative HPLC Trace for [18F]FLT (Method A).
Figure 3. Standard HPLC Tracerlab FXFN configuration for production of [
18F]FLT or [18F]FAZA.
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Method B: 2,30-anhydro-cyclic precursor: To prepare FLT using
Method B, the Tracerlab synthesis module was used in the
original ‘out-of-the-box’ configuration illustrated in Figure 3 and
reagent vials were loaded as follows: Vial 1: potassium carbonate
(3.5 mg in 0.5 mL water); Vial 2: kryptofix-2.2.2 (15 mg in 1 mL
MeCN); Vial 3: 2,30-anhydro-cyclic precursor (10 mg in 1.0 mL
DMSO); Vial 4: NaOH (0.25 M, 0.35 mL); Vial 5: aq. sodium
dihydrogen phosphate (0.25 M, 0.75 mL); Vial 6: semi-preparative
HPLC mobile phase (5% EtOH: 95% 10 mM sodium dihydrogen-
phosphate, 1.75 mL).
Following drying of the fluoride using the general procedure,
2,30-anhydro-cyclic FLT precursor (10 mg in 1 mL DMSO) was
added and the reaction vessel was heated at 1601C for 10 min.
After this time the reaction was cooled to 501C and 0.25 M NaOH
(0.35 mL) was added for deprotection. The deprotection was
heated at 501C for 4 min after which time the reaction was
neutralized with 0.25 M aq. sodium dihydrogen phosphate
(0.75 mL). The crude reaction mixture was diluted with 1.75 mL
of HPLC mobile phase, passed through an alumina Sep-Pak to
remove unreacted fluoride-18 and purified by semi-preparative
HPLC (column: Alltech Econosphere C18 10m, 250 10 mm;
mobile phase: 5% EtOH : 95% 10 mM sodium dihydrogenpho-
sphate (v/v); flow rate: 5.0 mL/min). A representative HPLC trace is
illustrated in Figure 5. The peak corresponding to [18F]FLT was
collected into the collection vial of the TracerLab, from which
it was then passed through a sterile Millipore Millex-GS filter into
a sterile dose vial. Doses were released for quality control testing
as described in Quality Control Procedures section, and the yield of
[18F]FLT using this method is 4.2% (nondecay corrected, n = 25).
Production of [18F]FAZA
Introduction: Tumor hypoxia results when tumor cells have been
deprived of oxygen, frequently occuring when a tumor has
outgrown its blood supply. It is important to determine if a tumor
is hypoxic as soon as possible, because such tumors are typically
resistant to radiotherapy and chemotherapy and require alter-
native treatment strategies. 2-Nitroimidazoles are an important
class of compound known to be retained in higher levels in
hypoxic tumor cells than the corresponding normoxic cells. The
reason for the increased uptake is that in a hypoxic environment
2-nitroimidazoles undergo intracellular reduction which leads to
fragmentation into species which are unable to pass back out
of the cell. An analogous process is also known to occur in
myochardial ischemia. 2-Nitroimidazoles have therefore been
adapted for use in molecular imaging of hypoxia. For example,
radioactive 2-nitroimidazole derivatives have been prepared,
such as [18F]-fluoroazomycin arabinoside ([18F]FAZA),30–35 that
are finding widespread use in diagnosis of tumor hypoxia and
monitroring subsequent response to therapy.
Synthesis procedures: To prepare FAZA, the Tracerlab synthesis
module was used in the original ‘out-of-the-box’ configuration
illustrated in Figure 3 and reagent vials were loaded as follows:
Vial 1: potassium carbonate (3.5 mg in 0.5 mL water); Vial 2:
kryptofix-2.2.2 (15 mg in 1 mL MeCN); Vial 3: FAZA precursor (5 mg
in 0.7 mL DMSO); Vial 4: NaOH (0.1 M, 1.0 mL); Vial 5: aq. sodium
dihydrogen phosphate (0.25 M, 0.5 mL); Vial 6: semi-preparative





Figure 5. Semi-preparative HPLC Trace for [18F]FLT (Method B).
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Following drying of the fluoride using the general procedure, a
solution of [18F]FAZA precursor (5 mg) in anhydrous DMSO
(0.7 mL) was added to the dried [18F]fluoride and the reaction
was heated to 1001C with stirring for 10 min. After this time, the
reaction was cooled to 401C and 0.1 M aqueous sodium hydroxide
(1 mL) was added. The reaction was stirred for 5 min at 401C to
hydrolyze the acetate protecting groups. After hydrolysis, the
crude reaction mixture was diluted with 0.25 M aqueous sodium
dihydrogen phosphate solution (0.5 mL) and HPLC mobile phase
(1 mL). The diluted reaction mixture was passed through an
alumina Sep-P ak cartridge and then purified by semi-preparative
HPLC (column: Alltech Econsosphere C18 10m, 250 10 mm;
mobile phase: 3% ethanol: 97% 10 mM sodium dihydrogenpho-
sphate (v/v); flow rate: 4 mL/min). The fraction corresponding to
[18F]FAZA (typically eluting between 20 and 23 min as shown in
Figure 6) was collected for 1 min into a vial precharged with 0.9%
sodium chloride, USP (3.8 mL) and sodium phosphates, USP
(0.2 mL). The final formulation (8 mL) was then passed through a
sterile filter into a sterile vial to provide [18F]FAZA in an isotonic
solution released for quality control testing as outlined in Quality
Control Procedures section. Typical yield of [18F]FAZA prepared
using this method is 4.8% (nondecay corrected, n = 25).
Tracerlab production with HPLC purification and
SPE reformulation
Production of [18F]MPPF
Introduction: The serotonin (5-hydroxytryptamine, 5-HT) recep-
tors are involved in a range of CNS functions but conversely
have also been implicated in a range of psychiatric disorders
such as depression, epilepsy, anxiety, Alzheimer’s disease and
schizophrenia. Therefore, PET radiopharmacueticals capable of
monitoring 5-HT receptor activity in the brain have potential for
diagnosing and monitoring response to treatment, a concept
recently reviewed by Pike.36 Indeed, [carbonyl-11C]WAY-100635
has been used routinely to detect 5-HT1A receptors for many
years now. However, the synthesis of [carbonyl-11C]WAY-100635
involves a Grignard reagent and, despite the efforts of many
groups37–40 and recent improvements,41 in our hands produc-
tion has always proven somewhat unreliable. Therefore, we
wished to make an alternative radiopharmaceutical available to
those physicians wishing to quantify 5-HT1A receptor activity,
with the aim ultimately of phasing out production of
[carbonyl-11C]WAY-100635. With this goal in mind, we have just
completed site qualification for clinical production of [18F]MPPF,
a fluorinated analog of WAY, at the University of Michigan.
[18F]MPPF has been shown to have very high selectivity for
5-HT1A receptors (Ki = 3.370.8 nM) and its use in both clinical
and preclinical PET imaging of 5-HT1A receptors has been
recently reviewed.42 Originally, the iodinated derivative
([125I]MPPI) was reported in 1994 by Kung and co-workers43
and subsequently, in 1997, they also prepared the fluorinated
analog ([18F]MPPF).44 In contrast to WAY, [18F]MPPF can simply
be prepared by nucleophilic fluorination, HPLC purification and
subsequent reformulation–such conditions have been opti-
mized by Le Bars et al.45
Synthesis procedures: To prepare [18F]MPPF, the Tracerlab FXFN
was configured as shown in Figure 7, incorporating the dilution




Figure 6. Semi-preparative HPLC Trace for [18F]FAZA.
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loaded as follows: Vial 1: potassium carbonate (3.5 mg in 0.5 mL
water); Vial 2: kryptofix-2.2.2 (15 mg in 1 mL MeCN); Vial 3: MPPF
precursor (10 mg in 0.5 mL DMSO); Vial 6: HPLC mobile phase
(3.0 mL), Vial 7: 0.9% sodium chloride for injection, USP (9.5 mL);
Vial 8: ethanol (0.5 mL); Vial 9: sterile water for injection, USP
(12 mL); round-bottomed flask: water (50 mL).
Following drying of the fluoride using the general procedure,
MPPF precursor (10 mg in 0.5 mL DMSO) was then added and
the reaction vessel was heated at 1401C for 20 min. After this time,
the reaction vessel was cooled to room temperature and the
crude reaction mixture was diluted, passed through an alumina
Sep-Pak and purified by semi-preparative HPLC (column: Pheno-
monex Luna C18, 250 10 mm; mobile phase: 55% 50 mM NaOAc
(pH = 5) : 18% THF : 27% MeOH (v/v); flow rate: 5 mL/min).
A representative HPLC trace is shown in Figure 8. The fraction
corresponding to [18F]MPPF was collected into the round-
bottomed dilution flask and simultaneously diluted into sterile
water. This solution was then passed through a Waters SDB-XC
Sep-Pak to trap the [18F]MPPF while washing away acetonitrile left
over from the HPLC buffer. Following trapping, the cartridge was
rinsed with sterile water (12 mL). [18F]MPPF was then eluted into
the collection vial with ethanol (0.5 mL) and diluted with sterile
saline (9.5 mL). The dose was then passed through a sterile filter
into a sterile dose vial and released for QC testing as per Quality
Control Procedures section. Typical yields of [18F]MPPF using this
method were 8.8% (nondecay corrected, n = 28).
Production of [18F]FEOBV
Introduction: Loss of cholinergic neurons has been documented
in a number of prevalent neurodegenerative diseases such as
Alzheimer’s Disease and the parkinsonian dementias.46–49 Further-
more, cholinergic function has been shown to correlate with
cognitive function parameters.50,51 There has therefore been great
interest in developing imaging agents to reliably quantify
cholinergic function in vivo. One such approach targets the
vesicular ACh transporter (VAChT) in cholinergic terminals with
radiolabeled forms of the drug vesamicol.52 A mounting body of
evidence points to VAChT as being a very specific marker of
cholinergic terminals, spurring a search for suitable radioligands
for measuring VAChT in vivo. With this goal in mind, we have
studied a class of analogs called benzovesamicols, discovered by
Rogers et al.,53 and identified a number of novel radiolabeled
benzovesamicol analogs which distribute in vivo in patterns that
correlate closely with the densities of marker proteins of the
cholinergic nerve terminal.54 Analogs with radioiodine, carbon-11,
or fluorine-18 labels at the 5 position of the 2-hydroxy-3-N-(4-
phenyl)-piperidino-tetralin frame-work, which we term 5-substi-
tuted-benzovesamicols, have shown particularly favorable ima-
ging properties. Human SPECT imaging studies with the
[123I]labeled benzovesamicol analogue [123I]IBVM show decreases
in tracer binding in several brain regions of AD patients.55,56 These
studies offer encouragement that appropriate benzovesamicol29
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Figure 7. Standard HPLC/Reformulation Tracerlab FXFN configuration for production of [
18F]MPPF or [18F]FEOBV.
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tracers can map cholinergic neurons and gauge the functional
integrity of cholinergic synapses in human subjects.
With the aim of extending human benzovesamicol imaging
studies to a higher level of precision with PET, we have
developed the novel fluorine-18-labeled agent, 5-fluoroethoxy-
benzovesamicol ([18F]-(-)FEOBV). We have conducted extensive
preclinical evaluation of [18F]FEOBV,57,58 and the results have
been extremely promising. Therefore, we have recently sub-
mitted an exploratory IND application to the US FDA to permit
introduction of [18F]FEOBV as an investigational cholinergic
synaptic tracer for human PET imaging studies.
Synthesis procedures: To prepare [18F]FEOBV, the Tracerlab
FXFN was configured as shown in Figure 7, incorporating the
dilution flask for the reformulation process, and reagent vials
were loaded as follows: Vial 1: potassium carbonate (3.5 mg in
0.5 mL water); Vial 2: kryptofix-2.2.2 (15 mg in 1 mL MeCN); Vial 3:
FEOBV precursor (0.2–0.5 mg in 0.5 mL DMSO); Vial 6: sterile
water (2.0 mL)/acetonitrile (1.5 mL); Vial 7: 0.9% sodium chloride
for injection, USP (9.5 mL); Vial 8: ethanol (0.5 mL); Vial 9: sterile
water for injection, USP (10 mL); round-bottomed dilution flask:
sterile water (40 mL).
Following drying of the fluoride using the general procedure
FEOBV precursor (0.2–0.5 mg) dissolved in anhydrous DMSO
(0.5 mL) was then added to the reactor vessel. The reaction
mixture was then heated at 1201C for 10 min and then cooled to
501C. The resulting mixture was diluted with 3.5 mL of an
aqueous acetonitrile solution. The diluted reaction mixture was
passed through a Sep-Pak Light Alumina-N, and loaded onto a
semi-preparative HPLC (column: Phenomenex Synergi Polar-RP,
10 250 mm; mobile phase: 45% MeCN : 55% aqueous 50 mM
ammonium acetate; flow rate = 4 mL/min). The single peak
corresponding to [18F]FEOBV eluted between 30 and 40 min
(Figure 9). That product fraction was collected, diluted into
40 mL of sterile water, and passed through a C-18 Sep-Pak which
was then washed with 10 mL of sterile water. [18F]FEOBV was
then eluted with 0.5 mL of EtOH (USP for injection) and collected
in the Tracerlab FXFN product vial. The Sep-Pak was washed with
9.5 mL of saline to bring the final formulation volume to 10 mL.
The final drug product was dispensed into a septum sealed,
sterile, pyrogen-free glass vial through a 0.22 mm sterile filter and
submitted for QC testing as outlined in Quality Control
Procedures section. Typical yields of [18F]FEOBV using this
method were 9.4% (nondecay corrected, n = 10).
Tracerlab production with SPE purification
Production of [18F]sodium fluoride
Introduction: Globally, about 70 000 nuclear medicine diagnostic
imaging procedures, including bone imaging, are performed
using technetium-99m every day.59 Technetium-99 m is ob-
tained as the decay product from molybdenum-99, but despite
this demand, only six nuclear reactors worldwide are capable of
producing molybdenum-99. During 2009, the Chalk River
nuclear reactor in Canada has been shutdown for unscheduled
repairs leaving thousands of hospitals in North America without
a supply of technetium-99m and a crisis in the molecular
imaging community.59,60
Consequently, alternatives to technetium-99m scans are in
high demand and [18F]sodium fluoride represents an easily
accessible PET imaging alternative to technetium-99m bone
imaging agents.61,62 In an effort to address the worldwide 29
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Figure 8. Semi-preparative HPLC trace for [18F]MPPF.
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shortage of technetium-99m, the US Centers for Medicare and
Medicaid Services (CMS) are investigating the effectiveness of
[18F]sodium fluoride as an imaging agent for bone metastasis (to
monitor the spread of, for example, breast cancer to the bone)
and is re-evaluating their noncoverage policy. In 2010 they
agreed limited reimbursement for those patients on a clinical
trial and therefore, PET centers worldwide have an immediate
and urgent need for easy access to [18F]sodium fluoride suitable
for clinical use.
Synthesis procedures: We recently reported a preparation of
[18F]sodium fluoride,13 in which a Tracerlab FXFN was reconfi-
gured to allow full automation of the method for producing
sodium fluoride reported by Nandy et al..63 The Tracerlab was
configured as shown in Figure 10 and vials were loaded as
follows: vial 7: 0.9% sodium chloride, USP for injection (10 mL);
vial 9: sterile water for injection, USP (10 mL); dilution flask sterile
water for injection, USP (10 mL). The delivery line from the
cyclotron was connected to the dilution flask via plastic luer lock
fittings which enable easy switching between delivery of
fluoride to the target vial for a routine synthesis, and delivery
to the dilution flask for preparation of [18F]sodium fluoride.
Furthermore, these fittings allow easy incorporation of Sep-Paks
into the target delivery line.
A QMA-light Sep-Pak, preconditioned by flushing with
ethanol (10 mL) followed by Sterile Water for Injection, USP
(10 mL), was placed in the C18 cradle (between V15 and V17), a
Plus-CM cation exchange cartridge was incorporated into the
target delivery line and a sterile product vial with appropriate
sterile filters was attached to the product delivery line. Note that
since [18F]sodium fluoride is prepared using the reformulation
portion of the Tracerlab FXFN synthesis module, a feature that is
common to other Tracerlab modules including the Tracerlab
FXc-pro, this method can easily be transferred to other synthesis
modules.
Fluoride-18 was delivered to the dilution flask through an in-
line Plus-CM cation exchange cartridge (to remove positively
charged recoil nuclei generated concomitantly with fluoride-18
in the cyclotron target). Following completion of the cyclotron
delivery, the solution of fluoride-18 was then transferred
(Ar pressure) through the QMA-light Sep-Pak, trapping the
fluoride-18 and passing the water to waste. Following trapping,
the QMA-light Sep-Pak was then washed with an additional
10 mL of Sterile Water for Injection, USP to remove residual
[18O]H2O. The fluoride-18 was then eluted into the Tracerlab
collection vial using 0.9% Sodium Chloride (10 mL) with
concomitant generation of [18F]sodium fluoride. The 10 mL
dose was passed through a sterile Millipore Millex-GS filter into a
sterile dose vial and submitted for quality control testing (see
experimental section). Typical yields of [18F]sodium fluoride were
495% (nondecay corrected, n = 10).
Production of [18F]fluorocholine
Introduction: Choline is a salt that is found in all cells where it is
essential for the biosynthesis of phospholipids.64 Such phos-
pholipids are then incorporated into cell membranes and
therefore radiolabeled analogs of choline can be used to
monitor the rate of production of cell membranes in vivo, and
thus rate of cell proliferation. Like [18F]FLT, radiolableled choline
derivatives find widespread use in clinical PET imaging of tumors
and [11C]choline has been used as a biomarker to image human
brain, lung and prostrate tumors.65,6630
0
Figure 9. Semi-preparative HPLC trace for [18F]FEOBV.
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However, as the field of PET imaging expands and demand for
PET tracers at hospitals not possessing a cyclotron continues to
grow, there is a concerted effort toward developing the
corresponding fluorine-18-labeled analogs of high demand
carbon-11-labeled radiopharmaceuticals. The favorable half-life
of fluorine-18 (110 min), when compared with that of carbon-11
(20 min), facilitates distribution of radiopharmaceuticals from
radiochemistry production facilities to satellite PET centers that
do not possess cyclotrons. With this in mind, in 2001 DeGrado et
al. reported a synthesis of [18F]fluorocholine from the reactive
intermediate [18F]fluorobromomethane.67,68 Subsequently,
others have also prepared [18F]fluorocholine from [18F]fluoro-
methyl triflate.69 DeGrado’s method has also been adapted for
SPE purification, allowing automated production of [18F]fluoro-
choline on a TracerLab MXFDG, by Kryza et al.
15
As the demand for [18F]fluorocholine from our PET center has
increased heavily of late, we decided to adapt Kryza’s method
for use on a TracerLab FXFN, and herein report the first results
from these research efforts.
Synthesis procedures: The TracerLab FXFN was configured as
shown in Figure 11 and the reagent vials were loaded as follows:
Vial 1: potassium carbonate (3.5 mg in 0.5 mL water); Vial 2:
kryptofix-2.2.2 (15 mg in 1 mL MeCN); Vial 3: dibromomethane
(300 mL in 0.7 mL MeCN); Vial 7: sterile water for injection, USP
(15 mL); Vial 8: 0.9% sodium chloride for injection, USP (3.0 mL);
Vial 9: ethanol (10.0 mL); C-18 Sep-Pak light: precharged with
N,N-dimethylamino ethanol (1 mL).
The front end of the synthesis module was configured as for a
typical radiofluorination reaction. The line from the reactor
needle out through V14 (normally connected to an alumina
cartridge as shown in Figures 3 and 4) was connected to
3 silica Sep-Pak cartridges connected in series. The third
silica cartridge was then connected (by luer fitting) to V17.
N,N-Dimethylamino ethanol (400 mL) was loaded onto a C18
Sep-Pak and then this was stacked on top of a CM-plus Sep-Pak
in the Tracerlab FXFN C18 cradle.
Following drying of the fluoride using the general procedure,
dibromomethane precursor was added to the reactor and the
reaction was heated to 951C for 5 min. After this time, the
reactor was cooled (401C), and the [18F]fluorobromomethane
was distilled through 3 silica Sep-Paks, C18 Sep-Pak and,
finally, the CM Sep-Pak to waste. The argon supply to the
TracerLab FXFN synthesis module is fixed at 40 psi and this was
used to transfer the crude reaction mixture. 3 silica Sep-Paks
removed any unreacted dibromomethane (b.p. = 971C) and
aceteonitrile (b.p. = 821C) that, despite their higher boiling
points, may otherwise have distilled over. Nonvolatile compo-
nents, including kryptofix-2.2.2 and potassium carbonate,
remained in the reaction vessel. In contrast, the volatility of
[18F]fluorobromomethane (b.p. = 91C) allowed pseudo-distilla-
tion over to valve-17 where it was trapped on the C18 cartridge
and concomitantly reacted with DMAE (400 mL) to generate
[18F]fluoromethylcholine. After 10 mins of distillation, the C18
Sep-Pak cartridge was washed with ethanol to elute the
[18F]fluoromethylcholine as well as unreacted [18F]fluorobromo-
methane and DMAE. As [18F]fluoromethylcholine is positively
charged it was trapped on the CM-Plus cation exchange resin,
while the uncharged precursor species were washed to waste.
The CM was then washed with Sterile Water for Injection, USP to
remove any residual solvents and by-products. Finally, [18F]fluor-
omethylcholine was eluted from the CM-Plus Sep-Pak into the
collection flask with sterile saline (3 mL). The dose was passed
through a sterile filter into a sterile dose vial and released for
quality control testing (Quality Control Procedures section).
Typical nondecay corrected yields of [18F]fluoromethylcholine
using this optimized production method were 5%, (n = 7). Doses 30
1
Figure 10. Modified Tracerlab FXFN configuration for [
18F]sodium fluoride production.
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were free of residual solvents, kryptofix-2.2.2 and dibromo-
methane, but were found to contain residual DMAE
(100–000 mg/mL). The radiochemical yield of fluorocholine, and
levels of residual DMAE, were similar to that reported by Kryza
et al.,15 and proved acceptable for our current preclinical
demands. Nevertheless, optimization of this chemistry, particu-
larly exploiting recent improvements reported by Slaets et al.,70
is ongoing in our laboratory.
Production of [18F]SFB
Introduction: Labeling of large bioactive molecules such as
peptides, proteins and antibodies with fluorine-18 typically
requires prior formation of a smaller labeled prosthetic group.
A number of strategies have been reported which allow such
labeling including alkylation, acylation, amidation and radio-click
chemistry. Of these approaches, acylation with N-succinimidyl-4-
[18F]fluorobenzoate ([18F]SFB) is the workhorse, routinely pro-
viding fluorine-18-labeled bioactive molecules in high radio-
chemical yield. Until recently, however, production of [18F]SFB
was not trivial and required a three-step radiochemical synthesis
which used multiple reaction vessels. Typically this is done
manually,71 but the process has also been automated,16,72
although successful automation does require access to synthesis
modules possessing multiple reaction vessels. A breakthrough
came when Kabalka and co-workers reported a one-pot
synthesis of [18F]SFB requiring only Sep-Pak purification.73 We
recently reported a fully automated synthesis of [18F]SFB,
adapted from Kabalka’s original report and exploiting the
spectacular chemistry originally reported by Haka et al.,74 using
a Tracerlab FXFN synthesis module.
11 Concurrent with our efforts
in this area, Tang et al. reported a related automated synthesis
of [18F]SFB, also employing a Tracerlab FXFN.
22
Synthesis procedures: To prepare [18F]SFB, the Tracerlab was
configured as shown in Figure 12 and vials were loaded as
follows: Vial 1: potassium carbonate (3.5 mg in 0.5 mL water);
Vial 2: kryptofix-2.2.2 (15 mg in 1 mL MeCN); Vial 3: 4-
(ethoxycarbonyl)-N,N,N-trimethylbenzenaminium triflate precur-
sor (5 mg in 0.5 mL DMSO); Vial 4: TPAH (20 mL in 0.5 mL MeCN);
Vial 5: acetonitrile (1 mL); Vial 6: TSTU (10 mg in 0.6 mL MeCN);
Vial 7: MeCN (2 mL); Vial 9: 10% MeCN in water (10 mL); dilution
flask: 5 mL of 5% acetic acid and 15 mL water.
Following drying of the fluoride using the general procedure,
the trimethylbenzeneaminium triflate precursor (5 mg in 0.5 mL
DMSO) was added to the reactor and the reaction vessel was
heated to 901C for 10 min to provide [18F]ethyl 4-fluorobenzo-
ate. After this time, tetrapropylammonium hydroxide (TPAH,
20 mL in 0.5 mL MeCN) was added to saponify the ester group.
Heating at 1201C for 3 min provides [18F]4-fluorobenzoic acid as
the corresponding TPA salt. After saponification, O-(N-succini-
midyl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TSTU,
10 mg in 0.6 mL MeCN) was added and the reaction vessel
was heated at 901C for 5 min to provide [18F]SFB. The crude
reaction mixture was then cooled down (401C) and transferred
to the round-bottomed dilution flask (precharged with 10 mL of
1.5% acetic acid) and the resulting solution was transferred
through a Waters C18 Plus Sep-Pak. The C18 Sep-Pak was then
washed with 10% MeCN (10 mL) to elute off unwanted
hydrophilic impurities including unreacted fluoride-18. Follow-
ing washing, [18F]SFB was eluted off into the collection vial with
neat MeCN (2 mL). Typical yields of [18F]SFB using this method
were 38% (nondecay corrected, n = 20) and radiochemical purity30
2
Figure 11. Modified Tracerlab FXFN configuration for [
18F]fluorocholine production.
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is always 495%. The [18F]SFB can be used as the obtained
solution in MeCN or, alternatively, can be evaporated to dryness
(heat gun) and re-dissolved in a solvent more appropriate for
the subsequent coupling reaction (e.g. DMSO).
Synthesis module cleaning
The radiopharmaceuticals described in the earlier sections can
be prepared on a single Tracerlab FXFN. Changing between
module configurations is straightforward if the luer-lock fittings
described in Introduction section are incorporated into the
Tracerlab. However, module reconfiguration does raise the issue
of how best to clean and dry the module between syntheses,
especially syntheses using different module setups. In order to
accomplish this reliably, the Tracerlab is returned to its basic
configuration (Figure 3), after completion of a given synthesis,
and then Clean, Clean-Disinfect, and Dry cycles are performed as
outlined below. Note that the round-bottomed dilution flask
and product collection vial are removed, washed and oven-dried
separately between syntheses and after completion of the
cleaning cycles. The reaction vessel should be checked after-
wards to ensure cleanliness and can also be further cleaned and
oven-dried manually if required. It is recommended that the
reactor be cleaned in this fashion at least once a week.
Clean cycle
Vials 1, 4, 5, 6, 7 and 9 are charged with sterile water. The
water from vials 1, 4, 5 and 6 is washed into the reactor and then
out, through the HPLC load loop, to waste. Similarly, the water
from vials 7 and 9 is washed through the lines connecting the
vials to V-17 and subsequently to waste. This ensures that the
main lines of the synthesis module all get washed with sterile
water.
Clean-disinfect cycle
Vials 1–6 are charged with 70% ethanol in sterile water. The 70%
ethanol from all of the vials is washed into the reactor and then
out, through the HPLC load loop, to waste. Moreover, 70%
ethanol is pumped through the HPLC column and associated
lines. During this cycle, the product collection vial is also washed
with 70% ethanol to disinfect it. These steps ensure that the
main lines of the synthesis module are sterilized during the
clean and disinfect cycle, and that the HPLC column is stored
under 70% ethanol between runs.
Dry cycle
Vials 1–6 are charged with acetone. The acetone from all of the
vials is washed into the reactor and the reactor is then heated to
801C for 5 min. After this time, the reactor is cooled and the
acetone is pushed out, through the HPLC load loop, to waste.
Subsequently, all of the vials and lines are dried with both argon
pressure and vacuum over 20 min, to ensure that all water and
acetone are removed from the synthesis module.
Quality control procedures
Quality control of radiopharmaceuticals prepared at the
University of Michigan PET Center for clinical use is carried out
according to the US Pharmacopeia [USP-32, NF-27, 2009] as 30
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Figure 12. Modified Tracerlab FXFN configuration for [
18F]SFB production.
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detailed below. After successfully meeting all release criteria,
doses are released to physicians for clinical use.
Visual inspection
Doses are visually examined and must be clear, colorless and
free of particulate matter.
Dose pH
The pH of the doses is analyzed by applying a small amount of
the dose to colorpHast
s
pH 2.0–9.0 nonbleeding pH-indicator
strips and determined by visual comparison to the scale
provided.
Chemical purity and radiochemical purity/identity
Chemical and radiochemical purity/identity are analyzed using a
Shimadzu VP-Series HPLC equipped with a Bioscan FC3300
radioactivity detector and either a conductivity detector
([18F]NaF; [18F]fluorocholine) or a UV detector ([18F]FLT,
[18F]FAZA, [18F]MPPF, [18F]FEOBV, [18F]SFB) using conditions
described below. While radiochemical purity for doses must be
495%, there are currently no chemical purity requirements for
release of radiopharmaceuticals in clinical research. However, we
calculate chemical purity by normalizing to a specific activity of
2 Ci/mmol. Doses are typically 100% chemically pure. Radio-
chemical identity is confirmed and quantified by calculating the
relative retention time (RRT = [retention time of radiochemical
peak] / [retention time of unlabelled reference standard peak]).
[18F]FLT
Condition A: Column: Phenomonex Luna C18(2) 5 m,
150 2.0 mm; mobile phase: 5% MeCN/20 mM NH4OAc, pH:
4.5; flow rate: 0.5 mL/min; oven: 401C; UV: 254 nm, RT = 6.5 min;
Condition B: Column: Phenomonex Synergi Hydro-RP,
150 4.6 mm; mobile phase: 10% EtOH in water; flow rate:
1.0 mL/min; UV: 254 nm, RT = 7.8 min [19F]FLT nonradioactive
fluoride-19 reference standard was purchased from ABX
Advanced Biochemicals.
[18F]FAZA
Column: Phenomonex Luna C8(2) 5 m, 100 2.0 mm; 5%
acetonitrile: 95% 20 mM aqueous ammonium acetate, pH 4.5;
flow rate: 0.5 mL/min, UV = 254 nm, RT = 6.2 min. [19F]FAZA
reference standard was purchased from Prof. Friedrich Ham-
merschmidt (Universität Wien, Austria) and Prof. Hans-Jürgen
Machulla (Steinbeis Transfer Center Radiopharmacy, Germany).
[18F]MPPF
Column: Phenomonex Luna C8(2) 5 m, 100 2.0 mm; mobile
phase: 35% MeOH/20 mM NH4OAc, pH: 4.5; flow rate: 0.8 mL/
min; oven: 401C; UV: 254 nm, RT = 5.6 min. [19F]MPPF nonra-
dioactive reference standard was purchased from ABX Advanced
Biochemicals.
[18F]FEOBV
Column: Phenomenex Gemini C18 5m, 50 2.0 mm; mobile phase:
40% acetonitrile, 60% water, 0.2% aqueous diethylamine; flow rate:
0.8 mL/min; oven: 401C; UV: 260 nm, RT = 4.6–4.8 min. [19F]FEOBV
nonradioactive reference standard was prepared in house.
[18F]Sodium fluoride
Column: Phenomonex Rezex RHM-monosaccharide (hydrogen
form), 300 7.8 mm; obile phase: 0.0015 M aqueous sulfuric
acid; flow rate: 0.8 mL/min, RT = 8.8 min. Sodium fluoride
(99.99%) was purchased from Sigma Aldrich and used as the
nonradioactive fluoride-19 reference standard.
[18F]Fluorocholine
Column: Waters IC-Pak Cation M/D Column, 150 3.9 mm;
mobile phase: 5 mM aqueous hydrochloric acid, flow rate:
1.0 mL/min; conductivity detector: negative polarity,
RT = 7.0 min. [19F]Fluoromethyl choline nonradioactive reference
standard was purchased from ABX Advanced Biochemicals.
[18F]SFB
Column: Chromolith RP18, 100 4.6 mm (Merck, Germany);
Mobile Phase: 0.1%TFA in 50% MeOH, flow rate: 0.8 mL/min;
UV: 254 nm, RT: 3.0 min. [19F]SFB nonradioactive reference
standard was purchased from ABX Advanced Biochemicals.
Radionuclidic identity
Radionuclidic identity is confirmed by measuring the half-life of
radiopharmaceutical doses and comparing it to the known half-
life of fluorine-18 (109.77 min). Activities are measured using a
Capintec CRC
s
-15R Radioisotope Dose Calibrator and half-life is
calculated using Equation (1). Calculated half-life must be
105–115 min.
T1=2 ¼ln2ðTime Difference=ðlnðending activity=starting activityÞÞÞ
ð1Þ
Residual solvent analysis
Levels of residual solvents in doses were analyzed using a
Shimadzu GC-2010 with an AOC-20 autoinjector, split/splitless
inlet, a flame ionization detector (FID) and a Restek column
(Stabilwax 30 m 0.25 mm, 0.25 m G16 stationary phase).
Radionuclidic purity
Radionuclidic purity is analyzed by gamma-ray spectrometry
and doses from the University of Michigan are allowed to decay,
and then sent out to a CRO (Dade Moeller and Associates,
Gaithersburg, MD) to test for the presence of long-lived
radioactive contaminants.
Sterile filter integrity test
Sterile filters from doses (with needle still attached) are
connected to a nitrogen supply via a regulator. The needle is
then submerged in water and the nitrogen pressure gradually
increased. If the pressure is raised above the filter acceptance
pressure (typically 50 psi) without seeing a stream of bubbles,
the filter is considered intact.
Bacterial endotoxins
Endotoxin content in radiopharmaceutical doses is analyzed by
a Charles River Laboratories EndoSafe
s
Portable Testing System
and according to the US Pharmacopeia. Doses must contain
o175 EU.30
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Sterility
Culture tubes of fluid thioglycolate media (FTM) and soybean
casein digest agar media (SCDM) are inoculated with samples of
[18F]-labeled radiopharmaceutical doses and incubated (along
with positive and negative controls) for 14 days. FTM is used to
test for anaerobes, aerobes and microaerophiles while SCDM is
used to test for nonfastidious and fastidious microorganisms.
Culture tubes are visually inspected on the 3rd, 8th and 14th days
of the test period and compared with the positive and negative
standards. Positive standards must show growth (turbidity) on the
plates and dose/negative controls must have no culture growth
after 14 days to be indicative of sterility (Table 1).
Conclusions
In conclusion, the Tracerlab FXFN has proven a versatile and
efficient automated synthesis module in our hands. The results
disclosed herein demonstrate that through simple incorporation
of luer lock fittings, the synthesis module can be configured
(and re-configured) in a straightforward manner to allow
production of clinical doses of many different radiopharma-
ceuticals. As proof-of-concept, the production of each radio-
pharmaceutical discussed in this paper uses a different state-of-
the-art radiochemical technique. Each synthesis has been fully
automated and all radiopharmaceutical doses for clinical use
meet and exceed established quality control criteria.
Acknowledgements
The University of Michigan Cyclotron and Radiochemistry
Group gratefully acknowledges the Office of Biological Research
(BER) of the Office of Science (SC), US Department of Energy
(DE-FG02-08ER64645) and the National Institutes of Health
(NIH NS15655) for financial support of this research, and
Siemens Molecular Imaging and Biomarker Research for dona-
tion of a test sample of the Boc-Boc-Nosyl FLT precursor.
References
[1] F. Wuest, M. Berndt, T. Kniess, Ernst Schering Res. Found. Workshop
2007, 62, 182-213.
[2] P. J. H. Scott, Angew. Chem. Int. Ed. 2009, 48, 6001-6004.
[3] P. W. Miller, N. J. Long, R. Vilar, A. D. Gee, Angew. Chem. Int. Ed.
2008, 47, 8998-9033.
[4] S. M. Ametamey, M. Honer, P. A. Schubiger, Chem. Rev. 2008, 108,
1501-1516.
[5] G. Antoni, B. Långström, in Positron Emission Tomograpy (Eds.:
D. L. Bailey, D. W. Townsend, P. E. Valk, M. N. Maisey, Springer,
London, 2003, pp. 237–250.
[6] L. Cai, S. Lu, V. W. Pike, Eur. J. Org. Chem. 2008, 12, 2853–2873.
[7] F. Dolle, D. Roeda, B. Kuhnast, M. C. Lasne, Fluorine and Health
2008, 3–65.
[8] R. Schirrmacher, C. Wangler, E. Schirrmacher, Mini-Rev. Org. Chem.
2007, 4, 317–329.
[9] M. R. Kilbourn, X. Shao, in Fluorine in Medicinal Chemistry and
Chemical Biology (Ed.: I. Ojima), Wiley-Blackwell, Chichester, 2009,
361–388.
[10] B. Långström, O. Itsenko, O. Rahman, J. Label. Compd. Radio-
pharm. 2007, 50, 794-810.
[11] P. J. H. Scott, X. Shao, J. Label. Compd. Radiopharm. 2010, 53,
586–591.
[12] X. Shao, M. R. Kilbourn, Appl. Radiat. Isot. 2009, 67, 602–605.
[13] B. G. Hockley, P. J. H. Scott, Appl. Radiat. Isot. 2010, 68,
117–119.
[14] T. Mori, S. Kasamatsu, C. Mosdzianowski, M. J. Welch, Y. Yonekura,
Y. Fujibayashi, Nucl. Med. Biol. 2006, 33, 281–286.
[15] D. Kryza, V. Tadino, M. A. Filannino, G. Villeret, L. Lemoucheux,
Nucl. Med. Biol. 2008, 35, 255–260.
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